Innate Pharma SA (NASDAQ:IPHA)

Delayed Data
As of May 27
 +0.15 / +5.15%
Today’s Change
Today|||52-Week Range

Stock Price Forecast

The 6 analysts offering 12-month price forecasts for Innate Pharma SA have a median target of 10.40, with a high estimate of 12.65 and a low estimate of 7.69. The median estimate represents a +239.95% increase from the last price of 3.06.

Analyst Recommendations

The current consensus among 6 polled investment analysts is to Buy stock in Innate Pharma SA. This rating has held steady since May, when it was unchanged from a Buy rating.Move your mouse over past
months for detail


Earnings and Sales Forecasts

Current Quarter

Earnings per Share
Reporting Date

Earnings per Share

Move your mouse over a quarter or year to see how estimates have changed over time.

Growthquarterly --
Growthannually 99.14%


Growthquarterly --
Growthannually 243.06%
Key to the earnings and sales forecast charts.